Product Description
Alvimopan is used to help the bowel recover more quickly after bowel surgery, so that you can eat solid foods and have regular bowel movements. Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery. (Sourced from: https://medlineplus.gov/druginfo/meds/a608051.html)
Mechanisms of Action: OPRM Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bladder Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03216525 |
2017P000330 | P3 |
Recruiting |
Bladder Cancer |
2023-12-01 |
7% |
2025-10-10 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/02/2024 |
News Article |
Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting |
|
09/12/2023 |
News Article |
Alvimopan Market 2023 Key Factors, Business Strategies, Challenges and Forecasts to 2029 |
|
02/01/2023 |
News Article |
Darryle D. Schoepp, Ph.D., Former Merck and Eli Lilly Executive, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives |
|
11/04/2021 |
News Article |
Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose |